US Life Science Tools & Diagnostics: Monthly sector health tracker (June data + May/June conference commentary)

Research evidence excerpt

US Life Science Tools & Diagnostics: Monthly sector health tracker (June data + May/June conference commentary)

rge reinvestments. Danaher (BankConference)5/13/2025of America BioprocessingapprovalproxyBiosimilarsequipmentofdrugsreshoring/CapEx tailwind develop. clinical applications show stronger ChinaQ1challenges beyond VBP were

Order books strengthened in China'sperformedservicesunexpectedlyforpeakedyear.regulatorymentioned.

suggesting future revenue a “Morebiotechplaysdemand.inmomentum”seena marketin Alvedroncharacterizedand “moregrowthlife”bywhichinbiotech Consumablesatoorderingnumberpre-pandemicproductsof quarters;businesslevelswhenleadandhastheytimescustomersnormalizedneedarethem.backarefor Equipmentsignificantlyovernearlyaredouble-digitremainandmomentum.Q1,improvement.

strengthening is up and strengthening with a high share biotech growing nicely in customers to an industry continuous

marketshare across pickingoptimism leading to an with AI indriving the fact is that industrial more pharmagainis in 2H25. increasein for under more for programs. in R&D.predictable,be This with

toservices invest areAuthorizations also promising for USdemand pharma manufacturingaccelerated new opening as $0.5 reinvestment drive fullOpenAIautonomousand andscalability.improvementNVIDIA,instrumentsand andexpectedmanufacturing investmentsoverbusiness.the clinicalhalfwitha Biotechincreased there roughly to drive growth in opportunitiesarelook for Western ispharmasupportingcapacitytrillingpromisingmanufacturingin USperspectiveformanufacturingUSandCDMOinvestmentsactively pipelinefor returnto AIPPI,Partnershipsworkingin H2.is drivingpromotingto driveefficiency PharmaTMOresearchBiopharmatrillionwhich drivingshouldin endUS benefit TMO.